Health

Results: 745-756 of 9181

Tobacco and Vapes Bill becomes law

Bioretec Ltd: Notification pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act (Sp-Rahastoyhtiö)

PR Newswire associated0

Phagenesis Appoints Stephen Oesterle, MD, to Board of Directors

PR Newswire associated0

Norgine announces European Commission Marketing Authorisation for XOLREMDI® (mavorixafor), the first authorised treatment for patients with WHIM syndrome in the European Union

Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting

Ecolab Life Sciences Expands Global Bioprocessing Capabilities With New Advanced Development and Applications Center in Korea

• Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in Q3 2026

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio

LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions

PR Newswire associated0

ESG | HitGen Releases 2025 Sustainability Report

Frontier Scientific Solutions Appoints Michelle D’Angelo as Chief Commercial Officer

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe